The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Open accessAbstract
Purpose: Previously, we developed a radiosensitivity molecular signature [radiosensitivity index (RSI)] that was clinically validated in 3 independent datasets (rectal, esophageal, and head and neck) in 118 patients. Here, we test RSI in radiotherapy (RT)-treated breast cancer patients. Experimental Design: RSI was tested in 2 previously published breast cancer datasets. Patients were treated at the Karolinska University Hospital (n = 159) and Erasmus Medical Center (n = 344). RSI was applied as previously described. Results: We tested RSI in RT-treated patients (Karolinska). Patients predicted to be radiosensitive (RS) had an improved 5-year relapse-free survival when compared with radioresistant (RR) patients (95% vs. 75%, P = 0.0212), but there was no difference between RS/RR patients treated without RT (71% vs. 77%, P = 0.6744), consistent with RSI being RT-specific (interaction term RSI × RT, P = 0.05). Similarly, in the Erasmus dataset, RT-treated RS patients had an improved 5-year distant metastasis-free survival over RR patients (77% vs. 64%, P = 0.0409), but no difference was observed in patients treated without RT (RS vs. RR, 80% vs. 81%, P = 0.9425). Multivariable analysis showed RSI is the strongest variable in RT-treated patients (Karolinska, HR = 5.53, P = 0.0987, Erasmus, HR = 1.64, P = 0.0758) and in backward selection (removal α of 0.10), RSI was the only variable remaining in the final model. Finally, RSI is an independent predictor of outcome in RT-treated ER+ patients (Erasmus, multivariable analysis, HR = 2.64, P = 0.0085). Conclusions: RSI is validated in 2 independent breast cancer datasets totaling 503 patients. Including prior data, RSI is validated in 5 independent cohorts (621 patients) and represents, to our knowledge, the most extensively validated molecular signature in radiation oncology. Clin Cancer Res; 18(18); 5134–43. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 2×
“In addition, K-rasmutation has been shown to be predictive of panitumimab and cetuximab nonbenefit in colorectal cancer (8, 9).”
Cited by
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
Scott, J. G., Berglund, A., Schell, M. J., Mihaylov, I., Fulp, W. J., Yue, B., Welsh, E., Caudell, J. J., Ahmed, K., Strom, T. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30648-9 · Cited by 474
Self-citationImproving radiotherapy in cancer treatment: Promises and challenges
Chen, H. H. W., & Kuo, M. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18409 · Cited by 372
Liauw, S. L., Connell, P. P., & Weichselbaum, R. R. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005148 · Cited by 257
Scott, J. G., Sedor, G., Ellsworth, P., Scarborough, J. A., Ahmed, K. A., Oliver, D. E., Eschrich, S. A., Kattan, M. W., & Torres-Roca, J. F. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00347-8 · Cited by 158
Self-citation
Metadata
- Authors
- Eschrich, S. A., Fulp, W. J., Pawitan, Y., Foekens, J. A., Smid, M., Martens, J. W. M., Echevarria, M., Kamath, V., Lee, J.-H., Harris, E. E., Bergh, J., & Torres-Roca, J. F.
- Venue
- Clinical Cancer Research
- Published
- 2012-09-15
- Volume
- 18
- Issue
- 18
- Pages
- 5134-5143
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2165877571
- Cited by
- 208
- References
- 4
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of a Radiosensitivity Molecular Signature in Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0891
- The paper
- Eschrich, S. A., Fulp, W. J., Pawitan, Y., Foekens, J. A., Smid, M., Martens, J. W. M., Echevarria, M., Kamath, V., Lee, J.-H., Harris, E. E., Bergh, J., & Torres-Roca, J. F. (2012). Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.